145
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Prevalence of cardiometabolic risk factors and metabolic syndrome in obese Kuwaiti adolescents

, , &
Pages 505-511 | Published online: 24 Oct 2014

Abstract

Background

Childhood and adolescent obesity is associated with insulin resistance, abnormal glucose metabolism, hypertension, dyslipidemia, inflammation, liver disease, and compromised vascular function. The purpose of this pilot study was to determine the prevalence of cardiometabolic risk factor abnormalities and metabolic syndrome (MetS) in a sample of obese Kuwaiti adolescents, as prevalence data might be helpful in improving engagement with obesity treatment in future.

Methods

Eighty obese Kuwaiti adolescents (40 males) with a mean (standard deviation) age of 12.3 years (1.1 years) participated in the present study. All participants had a detailed clinical examination and anthropometry, blood pressure taken, and assessment of fasting levels of C-reactive protein, intracellular adhesion molecule, interleukin-6, fasting blood glucose, insulin, liver function tests (alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase), lipid profile (cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides), insulin resistance by homeostasis model assessment, and adiponectin. MetS was assessed using two recognized criteria modified for use in younger individuals.

Results

The cardiometabolic risk factors with highest prevalence of abnormal values included aspartate aminotransferase (88.7% of the sample) and insulin resistance by homeostasis model assessment (67.5%), intracellular adhesion molecule (66.5%), fasting insulin (43.5%), C-reactive protein (42.5%), low-density lipoprotein cholesterol (35.0%), total cholesterol (33.5%), and systolic blood pressure (30.0%). Of all participants, 96.3% (77/80) had at least one impaired cardiometabolic risk factor as well as obesity. Prevalence of MetS was 21.3% according to the International Diabetes Federation definition and 30% using the Third Adult Treatment Panel definition.

Conclusion

The present study suggests that obese Kuwaiti adolescents have multiple cardiometabolic risk factor abnormalities. Future studies are needed to test the benefits of intervention in this high-risk group. They also suggest that prevention of obesity in children and adults should be a major public health goal in Kuwait.

Background

Childhood and adolescent obesity is associated with insulin resistance, abnormal glucose metabolism, hypertension, dyslipidemia, inflammation, liver disease, and compromised vascular function.Citation1Citation5 As with obesity, these impairments could track into young adulthood, which increases the risk of cardiometabolic diseases and even certain types of cancer independent of adult weight.Citation6,Citation7

The detrimental effects of adolescent obesity on subsequent risk of cardiovascular disease are partly mediated by the presence of cardiometabolic risk factors.Citation8 Cardiovascular disease is the leading cause of morbidity and mortality worldwide with an estimate of 17.3 million deaths in 2008, and by 2030 this number could reach up to 23.3 million.Citation9 It is widely believed that atherosclerosis begins in childhood and progresses into adulthood.Citation10,Citation11 As the number of cardiovascular disease risk factors increases in childhood, so does the severity of both coronary and aortic atherosclerosis in young adulthood.Citation3 In the Netherlands, two-thirds of obese children and adolescents had more than one cardiovascular disease risk factor in one study.Citation12 In Germany and Switzerland, around 50% of obese children had at least one cardiometabolic risk factor in one study.Citation13

The presence of obesity in childhood and adolescence is also related to the development of fatty liver or steatosis, which is the most common liver abnormality in this age group.Citation14 Steatosis can be present with or without elevated liver enzymes (aminotransferases).Citation15 For the long term, the ramifications of having persistently elevated liver enzymes and steatosis are important and could lead eventually to the development of cirrhosis.Citation14,Citation16

In two previous studies of obese adolescents in Kuwait, we observed that their health-related quality of life was unimpaired compared with nonobese peers,Citation17 and that their engagement with therapy to treat obesity was poor.Citation18 It is possible that knowledge of the presence of cardiometabolic risk factors in obese adolescents may increase the engagement of adolescents and their families with efforts to treat obesity. The aim of the present study was therefore to estimate the prevalence of cardiometabolic risk factors in obese adolescents in order to provide evidence that might be useful to future obesity treatment. In the present study, we carried out assessments of obesity-related cardiometabolic risk factors that could impair vascular health and liver function. These included lipid profile (cholesterol, low-density lipoprotein [LDL], very low-density lipoprotein, high-density lipoprotein [HDL], triglycerides [TG]), interleukin-6 (IL-6), intracellular adhesion molecule (ICAM), C-reactive protein (CRP), adiponectin, liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma glutamyltransferase [GGT]), and insulin resistance by homeostasis model assessment (HOMA-IR).

Materials and methods

Participants

The study was the baseline element of an intervention to treat adolescent obesity using a randomized controlled trial, the National Adolescent Treatment Trial for Obesity (NATTO).Citation18 We recruited 80 obese adolescents participating in the NATTO in Kuwait CityCitation18 at the preintervention stage of the trial. They were all at or above the age- and sex-adjusted 95th body mass index (BMI) percentile, which defines obesity.Citation19 Age ranged from 10 years to 14 years. All participants underwent physical examination including anthropometric assessment (weight, height, BMI, waist circumference) and had no medical or surgical history. All participants and their parents consented to take part in the study. The study was approved by the Medical Research Committee of the Ministry of Health – Kuwait.

Blood samples were drawn for analysis for fasting blood glucose (FBG), fasting insulin, cholesterol, LDL, HDL, TG, ALT, AST, GGT, CRP, IL-6, ICAM, and adiponectin. Insulin resistance was measured by HOMA-IR (fasting insulin × fasting glucose/22.5).Citation20

Blood pressure was measured when the participant was sitting quietly in the upright position, with the correct cuff size applied to the right arm. The reading was repeated three times, and the average of the three readings was taken.

Biochemical assessment

Cholesterol, TG, HDL, sensitive CRP, ALT, AST, and GGT assays were assessed using a C311 Roche analyzer; sensitive CRP immunotubidimetric assays with cholesterol, TG, HDL, ALT, AST, and GGT being enzymatic colorimetic. Kits were supplied by Roche Diagnosticx GmbH. IL-6, ICAM, adiponectin, and insulin analysis (enzyme-linked immunosorbent assays) was assessed using kits supplied by R&D Systems Europe Ltd (Oxford, UK) and Mercodia AB.

Cutoff points for defining the cardiometabolic risk factors and metabolic syndrome

There are two commonly used cutoff points for FBG (mmol/L), the World Health Organization (WHO) normal cutoff <6.1 mmol/LCitation21 and the American Diabetes Association normal cutoff <5.6 mmol/L.Citation22 However, in Kuwait, the official criterion used for diagnosing and classifying diabetes mellitus is the WHO criterion,Citation23 and so that was used in the present study.

Ideally, hyperinsulinemia is defined if insulin level exceeds the normal value according to the pubertal stage, due to the impact of physiological insulin resistance of puberty.Citation24 However, Tanner staging was not assessed during the clinical examination in the present study for social and cultural reasons. Thus, standard values of normal, borderline, and high fasting insulin levels proposed by the American Heart Association scientific statement were chosen.Citation25

HOMA-IR is a proxy for insulin resistance and is widely used in clinical settings and research, with high reliability in determining insulin resistance.Citation20 There is still a debate about the appropriate cutoff point for HOMA-IR, with proposed values of ≥2.5,Citation26,Citation27 ≥1.77,Citation28 and >3.16.Citation20 Keskin et alCitation20 found that HOMA-IR was the most sensitive and most specific of three proxies for defining insulin resistance, and the cutoff point for insulin resistance diagnosis based on HOMA-IR was 3.16,Citation20 so that definition was used in the present study.

Assessment of lipid profile for the participants included fasting TG, fasting cholesterol, fasting LDL, and fasting HDL. Jolliffe and JanssenCitation29 developed age- and sex-specific percentiles for lipoproteins and cholesterol, starting from age 12 years to age 20 years. However, our participants were aged 10–14 years, and it was not possible to use these lipoprotein percentiles for the whole sample. Therefore, the reference values for these parameters were taken from the National Cholesterol Education Program, with fixed cutoff points for normal, borderline, and high values regardless of sex and age.Citation30

Liver function tests were obtained in all participants and included ALT, AST, and GGT. The upper limit for ALT and AST in adults differs between populations, and differences exist between males and females.Citation31 However, in studies examining the prevalence of abnormal ALT, AST, and GGT in adolescents, the most commonly used cutoff points were >40 U/L, >40 U/L, and >35 U/L, respectively.Citation15,Citation32,Citation33 Therefore, these were the values that we used as cutoff points in our study.

Markers of inflammation were assessed in all participants, including CRP.Citation34 Generally, normal and abnormal levels of CRP were developed for the adult population,Citation34,Citation35 and some studies found that the normal range in healthy adults was from 0.08 mg/L to 6.1 mg/L.Citation36 Our study used the cutoff points set by the American Heart Association and the Centers for Disease Control and Prevention.Citation34

The inflammatory cytokine IL-6 has an age-related variability with peak physiological elevation around age 4 years and 15 years in relation to cartilage and bone development.Citation37 In the literature, precise reference ranges for IL-6 vary greatly depending on the age, weight status, and sex of the participants tested.Citation37Citation39 In the present study, we used the reference range of the control group (healthy controls n=37) from a study by Makni et alCitation40 (>3.9 pg/mL).

Inflammatory plasma soluble adhesion molecules (ICAM) were also measured in all of the participants.Citation41 The literature shows that ICAM values are age related, and when applying the cutoff point for our study we chose a study by Andrys et alCitation42 to establish reference range for serum soluble adhesion molecules in healthy children and adolescents aged 6–15 years, defined by values between the fifth and 95th percentiles for each inflammatory marker. The normal cutoff range for those aged 6–10 years was 206.8–486.8 ng/mL, and for those aged 11–15 years was 184.1–355.0 ng/mL.Citation42

The anti-inflammatory adipokine adiponectin was measured in all participants in the fasting state. It is normally present in plasma concentrations of 2–20 μg/mL.Citation43 Most studies comparing adiponectin concentration in obese adolescents with its concentration in healthy controls referred to “low levels” when adiponectin concentration was <5 μg/mL, as compared with its concentration in healthy control subjects at >10 μg/mL.Citation44Citation46 Therefore, in the present study, we used the same cutoff points.

Hypertension was defined as a systolic and or diastolic blood pressure ≥95th percentile for age, sex, and height, measured on three separate occasions.Citation47 Metabolic syndrome (MetS) was defined according to the International Diabetes Federation (IDF) definitionCitation48 and the Third Adult Treatment Panel (ATP III) definition.Citation49 Participants were classified as having MetS if they had a waist circumference ≥90th percentile plus two or more of the following criteria according to the IDF definition: TG ≥1.7 mmol/L, HDL <1.03 mmol/L, blood pressure ≥130/85 mmHg, and FBG ≥5.6 mmol/L. Classification of MetS according to the ATP III definition was based on the presence of three or more of the following criteria: waist circumference ≥90th percentile, TG ≥1.24 mmol/L, HDL ≤1.03 mmol/L, blood pressure ≥90th percentile, and FBG ≥6.1 mmol/L.

Results

Characteristics of study participants

shows the mean and standard deviation (SD) of all measured parameters for the participants (n=80). The mean age was 12.3 years (SD 1.1 years).

Table 1 Descriptive parameters of the adolescents according to sex, mean (standard deviation)

Prevalence of cardiometabolic risk factors

Twenty-six out of the 80 participants (32.5%) had systolic and/or diastolic blood pressure ≥95th percentile for age, sex, and height. Hyperglycemia and hyperinsulinemia were present in 2.5% (two of 80) and 43.8% (35/80) of participants, respectively. Insulin resistance as defined by HOMA-IR value >3.16Citation20 was found in 67.5% (54/80) of participants. Out of the 80 participants, 27.5% (22/80) had a high TG level, 33.8% (27/80) had a high total cholesterol level, 20% (16/80) had a low HDL level, and 35% had a high LDL level. Liver function tests showed high ALT in 26.3% (21/80) of participants, high AST in 88.8% (71/80) of participants, and high GGT level in 17.5% (14/80) of participants. CRP level was high in 42.5% (34/80) of participants, IL-6 level was high in 7.5% (six of 80) of participants, ICAM level was high in 66.3% (53/80) of participants, and adiponectin level was normal in all participants.

shows the results of waist circumference, TG, HDL, FBG, systolic blood pressure, and diastolic blood pressure measurements using IDF and ATP III criteria. Seventeen of the 80 participants (21.3%) met the diagnosis of MetS by the IDF definition and 24 of the 80 participants (30%) met the diagnosis of MetS by the ATP III definition.

Table 2 Metabolic syndrome prevalence using IDF and ATP III criteria in the participants

Discussion

The current study is the first to estimate the prevalence of cardiometabolic risk factors and MetS in a group of obese Kuwaiti adolescents. The main finding of this study was the high prevalence of multiple cardiometabolic risk factors. Out of the 16 risk factors measured, eight were high in ≥30% of the participants (). The cardiometabolic risk factors with the highest prevalence of abnormal values included AST (88.7% of the sample), HOMA-IR (67.5% of the sample), ICAM (66.5% of the sample), fasting insulin (43.5% of the sample), CRP (42.5% of the sample), LDL (35.0% of the sample), cholesterol (33.5% of the sample), and systolic blood pressure (30.0% of the sample); 96.3% (77/80) of participants had at least one cardiometabolic risk factor as well as obesity.

As mentioned previously, participants of this study were recruited from the baseline stage of a randomized controlled trial of an office-based treatment trial for adolescent obesity in Kuwait (NATTO). One of the findings of the NATTO was poor engagement with treatment, as evidenced by the poor attendance of families in both the intervention and control arms of the trial.Citation18 Therefore, findings from the present study might have been useful to demonstrate to the adolescents and their families that their obesity was a medical problem, and so possibly persuade them to engage more with treatment. Moreover, all of the measured parameters in the present study, except for adiponectin, are readily accessible by physicians working in the Ministry of Health – Kuwait in the clinical setting, so their measurement could be part of any treatment protocol for adolescent obesity in the future.

Risk factors for cardiovascular disease and type 2 diabetes mellitus have extended their roots to reach children and adolescents.Citation6,Citation7,Citation10,Citation50Citation54 In a study from IranCitation55 on 5,528 adolescents aged 10–18 years assessing the relationship between multiple cardiometabolic risk factors (total cholesterol, TG, LDL, HDL, blood pressure, and FBG) with BMI, low physical activity, and an unhealthy diet, BMI had the greatest direct effect on total cholesterol, LDL, TG, FBG, and blood pressure and an inverse relationship with HDL, more than that contributed by inactivity and an unhealthy diet. Kelishadi et alCitation55 called for immediate interventions to tackle pediatric obesity and its associated cardiometabolic risk factors in order to prevent future risk of MetS and chronic noncommunicable diseases in Iran.

Kardas et alCitation56 compared the levels of cholesterol, LDL, TG, HDL, FBG, blood pressure, vitamin D, and adiponectin between obese (n=63) and nonobese (n=51) Turkish adolescents aged 10–16 years. Obesity was defined as BMI >90th percentile for an age- and sex-specific Turkish reference population. Cholesterol, LDL, TG, FBG, and blood pressure were significantly higher in the obese group compared with the nonobese group. Adiponectin, vitamin D, and HDL were significantly lower in the obese group compared with the nonobese group. Mean adiponectin value for the obese group was 3.3 (±0.89) ng/mL and in the nonobese group the mean value was 6.0 (±1.4) ng/mL.

In the Netherlands, inpatient children and adolescents (n=80, aged between 8 years and 19 years) diagnosed with severe obesity (defined as BMI SDS ≥3 or BMI SDS ≥2.3 with comorbidities according to the growth percentiles of the Fourth Dutch Growth Study) were evaluated for the presence of multiple cardiometabolic risk factors, namely blood pressure, fasting insulin, FBG, HOMA-IR, cholesterol, LDL, TG, HDL, and CRP,Citation57 as part of an inpatient treatment trial for their obesity. Data showed that 80% of the participants had at least one impaired cardiometabolic risk factor as well as severe obesity. In comparison with our study, 90% of our participants had at least one impairment with regards to the same cardiometabolic risk factors assessed.

In the present study, almost a third of the participants had MetS according to the ATP III definition.Citation58 In a study done in Kuwait on apparently healthy female adolescents (n=431, age 10–19 years) to assess the prevalence of MetS using the same definitions that we applied to our study, it was found that MetS was present in 9.1% by the ATP III definition and 14.8% had MetS when the IDF definition was used.Citation59 In Saudi Arabia, the prevalence of MetS using the IDF definition was 18% among 180 obese 9- to 12-year-olds.Citation60 Also using the IDF definition in Lebanese adolescents, Nasreddine et alCitation61 found that 21.2% of the 104 obese adolescents (mean age 16±1.3 years) had MetS, 3.8% of the 78 overweight adolescents (mean age 16.4±1.4 years) had MetS, and 1.2% of the 81 healthy weight adolescents (mean age 16.8 years) had MetS. In Iran, according to the ATP III definition, MetS has been found in 3.3% of Iranian adolescents (n=450, age 15–18 years).Citation62 In a sample of 321 overweight, obese, and extremely obese adolescents from Brazil (obesity defined using the Centers for Disease Control and Prevention 2000 definition,Citation19 MetS was found in around 18% of the 10- to 16-year-old adolescents using the IDF definition.Citation63 Similarly, in the US,Citation64 it was found that >50% of obese children and adolescents (n=439, aged 4–20 years) had MetS according to definitions modified from ATP III and WHO.Citation24 In summary, global studies suggest that, as in the present study, MetS is relatively common among obese adolescents.

The present study had a number of strengths. Our participants were generally a fairly homogenous group of Kuwaiti adolescents living in Kuwait City and recruited from three State schools who were examined for the presence of cardiometabolic risk factors, including MetS. The use of traditional markers for cardiovascular disease (ie, lipid profile and blood pressure), multiple markers for inflammation (ie, CRP, IL-6, and ICAM), and, for the first time, adiponectin in a sample of Kuwaiti adolescents, assessment of insulin resistance as well as liver function, all add to the novelty of our study.

However, our study had a number of limitations. First, it was not possible to conduct Tanner staging, due to social/cultural and practical reasons. Second, the optimal cutoff to define abnormality for a number of the cardiometabolic risk factors is unclear, but widely used cutoffs were chosen for the present study. Third, no data on changes in cardiometabolic risk factors during obesity treatment were available. Improvements in cardiometabolic risk profile might increase engagement with obesity treatment. Nonetheless, the relatively high prevalence of abnormal values for cardiometabolic risk factors found in the present study could be a useful aid to engage more families into participating in adolescent obesity treatment in future, and might also increase the level of commitment to participation by those who do take part.

Conclusion

The present study suggests that a number of cardiometabolic risk factors and MetS are prevalent in obese Kuwaiti adolescents. This observation might provide impetus to future strategies to treat pediatric obesity and to prevent or delay the appearance of cardiovascular disease and diabetes mellitus in the future adult generation. The observation might also be used to encourage greater engagement with treatment among families.

Acknowledgments

We thank members of the Ethical Committee of the Ministry of Health – Kuwait for the opportunity. We also thank the research assistants, Badreya Al Mirshed and Dalal Al Fadhli, for their valuable work and adherence to the study protocol, and all staff of Al-Sabah laboratory and their head technician, Mrs Haifa’a Al-Mukhaizeem. Funding: Scottish Funding Council and Civil Services Commission – Kuwait.

Disclosure

The authors report no conflicts of interest in this work.

References

  • Franks PW Hanson RL Knowler WC Sievers ML Bennett PH Looker HC Childhood obesity, other cardiovascular risk factors, and premature death N Engl J Med 2010 362 6 485 493 20147714
  • Lenz A Diamond FBJr Obesity: the hormonal milieu Curr Opin Endocrinol Diabetes Obes 2008 15 1 9 20 18185058
  • Freedman DS Khan LK Dietz WH Srinivasan SR Berenson GS Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study Pediatrics 2001 108 3 712 718 11533341
  • Kolterman OG Gray RS Griffin J Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Invest Oct 1981 68 4 957 969
  • Al-Shawi A The dietary patterns and food habits of Kuwaiti housewives of 3 educational levels Education Journal of Kuwait University 1985 2 5 9 13
  • Beauloye V Zech F Tran HT Clapuyt P Maes M Brichard SM Determinants of early atherosclerosis in obese children and adolescents J Clin Endocrinol Metab 2007 92 8 3025 3032 17519311
  • Reilly JJ Methven E McDowell ZC Health consequences of obesity Arch Dis Child 2003 88 9 748 752 12937090
  • Juonala M Magnussen CG Berenson GS Childhood adiposity, adult adiposity, and cardiovascular risk factors N Engl J Med 2011 365 20 1876 1885 22087679
  • Alwan A Global status report on noncommunicable diseases 2010 World Health Organization 2011
  • Strong JP Malcom GT Newman WP3rd Oalmann MC Early lesions of atherosclerosis in childhood and youth: natural history and risk factors J Am Coll Nutr 1992 11 Suppl 51S 54S 1619200
  • Zieske AW Malcom GT Strong JP Natural history and risk factors of atherosclerosis in children and youth: the PDAY study Pediatr Pathol Mol Med 2002 21 2 213 237 11942537
  • van Emmerik NM Renders CM van de Veer M High cardiovascular risk in severely obese young children and adolescents Arch Dis Child 2012 97 9 818 821 22826539
  • l’Allemand-Jander D Clinical diagnosis of metabolic and cardiovascular risks in overweight children: early development of chronic diseases in the obese child Int J Obes 2010 34 Suppl 2 S32 S36
  • Schwimmer J Deutsch R Kahen T Lavine J Stanley C Behling C Prevalence of fatty liver in children and adolescents Pediatrics 2006 118 4 1388 1393 17015527
  • Strauss RS Barlow SE Dietz WH Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents J Pediatr 2000 136 6 727 733 10839867
  • Weiss R Kaufman FR Metabolic complications of childhood obesity: identifying and mitigating the risk Diabetes Care 2008 31 Suppl 2 S310 S316 18227502
  • Boodai SA Reilly JJ Health related quality of life of obese adolescents in Kuwait BMC Pediatr 2013 13 1 105 23845118
  • Boodai SA McColl JH Reilly JJ Randomised controlled trial of a good practice approach to treatment of adolescent obesity in Kuwait: National Adolescent Treatment Trial for Obesity in Kuwait (NATTO) Trials 2014 15 234 24943283
  • Kuczmarski RJ Ogden CL Grummer-Strawn LM CDC growth charts: United States Adv Data 2000 314 1 27 11183293
  • Keskin M Kurtoglu S Kendirci M Atabek ME Yazici C Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents Pediatrics 2005 115 4 e500 e503 15741351
  • World Health Organization Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation 2006
  • Genuth S Alberti KG Bennett P Follow-up report on the diagnosis of diabetes mellitus Diabetes Care 2003 26 11 3160 3167 14578255
  • Ahmed F Waslien C Al-Sumaie MA Prakash P Allafi A Trends and risk factors of hyperglycemia and diabetes among Kuwaiti adults: National Nutrition Surveillance Data from 2002 to 2009 BMC Public Health 2013 13 103 23379469
  • Alberti KG Zimmet PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabet Med 1998 15 7 539 553 9686693
  • Williams CL Hayman LL Daniels SR Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association Circulation 2002 106 1 143 160 12093785
  • Sharma S Lustig RH Fleming SE Identifying metabolic syndrome in African American children using fasting HOMA-IR in place of glucose Prev Chronic Dis 2011 8 3 A64 21477504
  • Madeira IR Carvalho CN Gazolla FM de Matos HJ Borges MA Bordallo MA Cut-off point for Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index established from Receiver Operating Characteristic (ROC) curve in the detection of metabolic syndrome in overweight pre-pubertal children Arq Bras Endocrinol Metabol 2008 52 9 1466 1473 Portuguese 19197455
  • Arshi M Cardinal J Hill RJ Davies PS Wainwright C Asthma and insulin resistance in children Respirology 2010 15 5 779 784 20456670
  • Jolliffe CJ Janssen I Distribution of lipoproteins by age and gender in adolescents Circulation 2006 114 10 1056 1062 16940191
  • Panel NE National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents Pediatrics 1992 89 3 495 501 1741227
  • Sohn W Jun DW Kwak MJ Upper limit of normal serum alanine and aspartate aminotransferase levels in Korea J Gastroenterol Hepatol 2013 28 3 522 529 22497339
  • Siest G Schiele F Galteau MM Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values Clin Chem 1975 21 8 1077 1087 1137913
  • Schwimmer JB McGreal N Deutsch R Finegold MJ Lavine JE Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents Pediatrics 2005 115 5 e561 e565 15867021
  • Pearson TA Mensah GA Alexander RW Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 2003 107 3 499 511 12551878
  • Jaye DL Waites KB Clinical applications of C-reactive protein in pediatrics Pediatr Infect Dis J 1997 16 8 735 746 quiz 46–47 9271034
  • Macy EM Hayes TE Tracy RP Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications Clin Chem 1997 43 1 52 58 8990222
  • Sack U Burkhardt U Borte M Schadlich H Berg K Emmrich F Age-dependent levels of select immunological mediators in sera of healthy children Clin Diagn Lab Immunol 1998 5 1 28 32 9455875
  • Warnberg J Moreno LA Mesana MI Marcos A Inflammatory mediators in overweight and obese Spanish adolescents. The AVENA Study Int J Obes Relat Metab Disord 2004 28 Suppl 3 S59 S63 15543221
  • Yamamura M Yamada Y Momita S Kamihira S Tomonaga M Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival Br J Haematol 1998 100 1 129 134 9450801
  • Makni E Moalla W Benezzeddine-Boussaidi L Lac G Tabka Z Elloumi M Correlation of resistin with inflammatory and cardiometabolic markers in obese adolescents with and without metabolic syndrome Obes Facts 2013 6 4 393 404 23970148
  • Martos R Valle M Morales RM Canete R Gascon F Urbano MM Changes in body mass index are associated with changes in inflammatory and endothelial dysfunction biomarkers in obese prepubertal children after 9 months of body mass index SD score loss Metabolism 2009 58 8 1153 1160 19477472
  • Andrys C Pozler O Krejsek J Derner V Drahosova M Kopecky O Serum soluble adhesion molecules (sICAM-1, sVCAM-1 and sE-selectin) in healthy school aged children and adults Acta Medica (Hradec Kralove) 2000 43 3 103 106 11089278
  • Oh DK Ciaraldi T Henry RR Adiponectin in health and disease Diabetes Obes Metab 2007 9 3 282 289 17391153
  • Goksen D Levent E Kar S Ozen S Darcan S Serum adiponectin and hsCRP levels and non-invasive radiological methods in the early diagnosis of cardiovascular system complications in children and adolescents with type 1 diabetes mellitus J Clin Res Pediatr Endocrinol 2013 5 3 174 181 24072086
  • Tascilar ME Cekmez F Meral C Evaluation of adipocytokines in obese children with insulin resistance Turk J Pediatr 2011 53 3 269 273 21980807
  • Alikasifoglu A Gonc N Ozon ZA Sen Y Kandemir N The relationship between serum adiponectin, tumor necrosis factor-alpha, leptin levels and insulin sensitivity in childhood and adolescent obesity: adiponectin is a marker of metabolic syndrome J Clin Res Pediatr Endocrinol 2009 1 5 233 239 21274300
  • National High Blood Pressure Education Program The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National High Blood Pressure Education Program (NHBPEP) Working Group on Children and Adolescents Pediatrics 2004 114 2 Suppl 4 555 576 15286277
  • Zimmet P Alberti KG Kaufman F The metabolic syndrome in children and adolescents: an IDF consensus report Pediatr Diabetes 2007 8 5 299 306 17850473
  • Cook S Weitzman M Auinger P Nguyen M Dietz WH Prevalence of a metabolic syndrome phenotype in adolescents: findings from the Third National Health and Nutrition Examination Survey, 1988–1994 Arch Pediatr Adolesc Med 2003 157 8 821 827 12912790
  • Poyrazoglu S Bas F Darendeliler F Metabolic syndrome in young people Curr Opin Endocrinol Diabetes Obes 2014 21 1 56 63 24247648
  • Herouvi D Karanasios E Karayianni C Karavanaki K Cardiovascular disease in childhood: the role of obesity Eur J Paediatr 2013 172 6 721 732
  • Weiss R Caprio S The metabolic consequences of childhood obesity Best Pract Res Clin Endocrinol Metab 2005 19 3 405 419 16150383
  • Visser M Bouter LM McQuillan GM Wener MH Harris TB Low-grade systemic inflammation in overweight children Pediatrics 2001 107 1 E13 11134477
  • Srinivasan SR Bao W Wattigney WA Berenson GS Adolescent overweight is associated with adult overweight and related multiple cardiovascular risk factors: the Bogalusa Heart Study Metabolism 1996 45 2 235 240 8596496
  • Kelishadi R Motlagh ME Roomizadeh P First report on path analysis for cardiometabolic components in a nationally representative sample of pediatric population in the Middle East and North Africa (MENA): the CASPIAN-III Study Ann Nutr Metab 2013 62 3 257 265 23635794
  • Kardas F Kendirci M Kurtoglu S Cardiometabolic risk factors related to vitamin d and adiponectin in obese children and adolescents Int J Endocrinol 2013 2013 503270 23983686
  • Makkes S Renders CM Bosmans JE van der Baan-Slootweg OH Seidell JC Cardiometabolic risk factors and quality of life in severely obese children and adolescents in The Netherlands BMC Pediatr 2013 13 62 23607651
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001 285 19 2486 2497 11368702
  • Al-Isa A Akanji AO Thalib L Prevalence of the metabolic syndrome among female Kuwaiti adolescents using two different criteria Br J Nutr 2010 103 1 77 81 19664298
  • Abdel-Megeid F Alfawaz H Metabolic syndrome and risk factors of cardiovascular diseases in obese children World Applied Science Journal 2012 20 7 988 996
  • Nasreddine L Naja F Tabet M Obesity is associated with insulin resistance and components of the metabolic syndrome in Lebanese adolescents Ann Hum Biol 2012 39 2 122 128 22324838
  • Mehrkash M Kelishadi R Mohammadian S Obesity and metabolic syndrome among a representative sample of Iranian adolescents Southeast Asian J Trop Med Public Health 2012 43 3 756 763 23077856
  • Rizzo AC Goldberg TB Silva CC Kurokawa CS Nunes HR Corrente JE Metabolic syndrome risk factors in overweight, obese, and extremely obese Brazilian adolescents Nutr J 2013 12 19 23363783
  • Weiss R Dziura J Burgert TS Obesity and the metabolic syndrome in children and adolescents N Engl J Med 2004 350 23 2362 2374 15175438